Aralast NP in Islet Transplant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Alpha-1 Antitrypsin

"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"

Trial Locations (1)

T6G 2C8

University of Alberta, Edmonton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

University of Alberta

OTHER

NCT02520076 - Aralast NP in Islet Transplant | Biotech Hunter | Biotech Hunter